Prothena (STU:0PT) Total Current Assets: €293.41 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:0PT Prothena Corp PLC STU:0PT
74 GF Score
Price €7.74
GF Value €12.82
! 3 Warning Signs
View Full Analysis

What is Prothena Total Current Assets?

Prothena STU:0PT -4.77% 74 Total Current Assets is €293.41 Mil as of Mar. 2026. GuruFocus rates STU:0PT with a GF Score™ of 74/100 and a GF Value™ of €12.82. The stock has 3 warning signs investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Prothena's total current assets for the quarter that ended in Mar. 2026 was €293.41 Mil.

Prothena  (STU:0PT) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Prothena's Liquidation Value for the quarter that ended in Mar. 2026 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=284.985-32.245+0.75 * 0+0.5 * 0
=252.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prothena Total Current Assets Related Terms

Prothena Total Current Assets Historical Data

* Premium members only.

The historical data trend for Prothena's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prothena Total Current Assets Chart

Prothena Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 517.56 678.83 586.22 463.57 269.18

Prothena Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 403.46 334.21 289.66 269.18 293.41
STU:0PT
74GF Score
Prothena Corp PLC STU:0PT
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prothena Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Prothena's Total Current Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=262.631+0+0+6.544
=269.18

Prothena's Total Current Assets for the quarter that ended in Mar. 2026 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=284.985+0+0+8.424
=293.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of €293.41 Mil mean?
Prothena (STU:0PT) has a Total Current Assets of €293.41 Mil as of Mar. 2026. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Prothena and its competitors.
Is Prothena's Total Current Assets too high?
Prothena's current Total Current Assets is €293.41 Mil. Overall, Prothena has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Prothena's Total Current Assets compare to CTNM and ASMB?
Prothena's Total Current Assets of €293.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Biotechnology company?
A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Prothena and its competitors. Prothena's current Total Current Assets is €293.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prothena stock overvalued right now?
Prothena (STU:0PT) has a current Total Current Assets of €293.41 Mil. The stock's GF Value™ is €12.82, compared to a current price of €7.74 — trading 39.6% below its estimated fair value. The current Total Current Assets is €293.41 Mil. Prothena's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Prothena (STU:0PT), the current Total Current Assets is €293.41 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prothena (STU:0PT) Overvalued in 2026?

Based on GuruFocus' analysis, Prothena stock appears to be undervalued. The current stock price of €7.74 is trading 39.6% below its estimated GF Value™ of €12.82.

Key valuation signals for STU:0PT:

  • Total Current Assets: €293.41 Mil
  • GF Value™: €12.82 vs. price of €7.74 (39.6% below fair value)
  • GF Score™: 74/100 with 3 warning signs

No single metric tells the full story. See the STU:0PT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prothena Business Description

Other Exchanges PRTA:USA0Y3M:UK0PT:Germany
Address 77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, Dublin, IRL, D02 VK60
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
74GF Score

Get the complete analysis for STU:0PT

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.74
Price
€12.82
GF Value